Literature DB >> 19746807

Automatic analysis of medial temporal lobe atrophy from structural MRIs for the early assessment of Alzheimer disease.

Piero Calvini1, Andrea Chincarini, Gianluca Gemme, Maria Antonietta Penco, Sandro Squarcia, Flavio Nobili, Guido Rodriguez, Roberto Bellotti, Ezio Catanzariti, Piergiorgio Cerello, Ivan De Mitri, Maria Evelina Fantacci.   

Abstract

The purpose of this study is to develop a software for the extraction of the hippocampus and surrounding medial temporal lobe (MTL) regions from T1-weighted magnetic resonance (MR) images with no interactive input from the user, to introduce a novel statistical indicator, computed on the intensities in the automatically extracted MTL regions, which measures atrophy, and to evaluate the accuracy of the newly developed intensity-based measure of MTL atrophy to (a) distinguish between patients with Alzheimer disease (AD), patients with amnestic mild cognitive impairment (aMCI), and elderly controls by using established criteria for patients with AD and aMCI as the reference standard and (b) infer about the clinical outcome of aMCI patients. For the development of the software, the study included 61 patients with mild AD (17 men, 44 women; mean age +/- standard deviation (SD), 75.8 years +/- 7.8; Mini Mental State Examination (MMSE) score, 24.1 +/- 3.1), 42 patients with aMCI (11 men, 31 women; mean age +/- SD, 75.2 years +/- 4.9; MMSE score, 27.9 +/- 1.9), and 30 elderly healthy controls (10 men, 20 women; mean age +/- SD, 74.7 years +/- 5.2; MMSE score, 29.1 +/- 0.8). For the evaluation of the statistical indicator, 150 patients with mild AD (62 men, 88 women; mean age +/- SD, 76.3 years +/- 5.8; MMSE score, 23.2 +/- 4.1), 247 patients with aMCI (143 men, 104 women; mean age +/- SD, 75.3 years +/- 6.7; MMSE score, 27.0 +/- 1.8), and 135 elderly healthy controls (61 men, 74 women; mean age +/- SD, 76.4 years +/- 6.1). Fifty aMCI patients were evaluated every 6 months over a 3 year period to assess conversion to AD. For each participant, two subimages of the MTL regions were automatically extracted from T1-weighted MR images with high spatial resolution. An intensity-based MTL atrophy measure was found to separate control, MCI, and AD cohorts. Group differences were assessed by using two-sample t test. Individual classification was analyzed by using receiver operating characteristic (ROC) curves. Compared to controls, significant differences in the intensity-based MTL atrophy measure were detected in both groups of patients (AD vs controls, 0.28 +/- 0.03 vs 0.34 +/- 0.03, P < 0.001; aMCI vs controls, 0.31 +/- 0.03 vs 0.34 +/- 0.03, P < 0.001). Moreover, the subgroup of aMCI converters was significantly different from controls (0.27 +/- 0.034 vs 0.34 +/- 0.03, P < 0.001). Regarding the ROC curve for intergroup discrimination, the area under the curve was 0.863 for AD patients vs controls, 0.746 for all aMCI patients vs controls, and 0.880 for aMCI converters vs controls. With specificity set at 85%, the sensitivity was 74% for AD vs controls, 45% for aMCI vs controls, and 83% for aMCI converters vs controls. The automated analysis of MTL atrophy in the segmented volume is applied to the early assessment of AD, leading to the discrimination of aMCI converters with an average 3 year follow-up. This procedure can provide additional useful information in the early diagnosis of AD.

Entities:  

Mesh:

Year:  2009        PMID: 19746807      PMCID: PMC2724178          DOI: 10.1118/1.3171686

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  54 in total

1.  Automated hippocampal segmentation by regional fluid registration of serial MRI: validation and application in Alzheimer's disease.

Authors:  W R Crum; R I Scahill; N C Fox
Journal:  Neuroimage       Date:  2001-05       Impact factor: 6.556

2.  Elastic model-based segmentation of 3-D neuroradiological data sets.

Authors:  A Kelemen; G Székely; G Gerig
Journal:  IEEE Trans Med Imaging       Date:  1999-10       Impact factor: 10.048

3.  Measuring size and shape of the hippocampus in MR images using a deformable shape model.

Authors:  Dinggang Shen; Scott Moffat; Susan M Resnick; Christos Davatzikos
Journal:  Neuroimage       Date:  2002-02       Impact factor: 6.556

4.  An automated technique for measuring hippocampal volumes from MR imaging studies.

Authors:  K M Gosche; J A Mortimer; C D Smith; W R Markesbery; D A Snowdon
Journal:  AJNR Am J Neuroradiol       Date:  2001-10       Impact factor: 3.825

5.  Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls.

Authors:  Jonathan H Morra; Zhuowen Tu; Liana G Apostolova; Amity E Green; Christina Avedissian; Sarah K Madsen; Neelroop Parikshak; Xue Hua; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage       Date:  2008-07-16       Impact factor: 6.556

Review 6.  Current concepts in mild cognitive impairment.

Authors:  R C Petersen; R Doody; A Kurz; R C Mohs; J C Morris; P V Rabins; K Ritchie; M Rossor; L Thal; B Winblad
Journal:  Arch Neurol       Date:  2001-12

7.  Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type.

Authors:  J G Csernansky; L Wang; S Joshi; J P Miller; M Gado; D Kido; D McKeel; J C Morris; M I Miller
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

8.  Mesial temporal sclerosis and temporal lobe epilepsy: MR imaging deformation-based segmentation of the hippocampus in five patients.

Authors:  R E Hogan; K E Mark; L Wang; S Joshi; M I Miller; R D Bucholz
Journal:  Radiology       Date:  2000-07       Impact factor: 11.105

9.  MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study.

Authors:  Tero Tapiola; Corina Pennanen; Mia Tapiola; Susanna Tervo; Miia Kivipelto; Tuomo Hänninen; Maija Pihlajamäki; Mikko P Laakso; Merja Hallikainen; Anne Hämäläinen; Matti Vanhanen; Eeva-Liisa Helkala; Ritva Vanninen; Aulikki Nissinen; Roberta Rossi; Giovanni B Frisoni; Hilkka Soininen
Journal:  Neurobiol Aging       Date:  2006-11-13       Impact factor: 4.673

10.  Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus.

Authors:  Olivier Colliot; Gaël Chételat; Marie Chupin; Béatrice Desgranges; Benoît Magnin; Habib Benali; Bruno Dubois; Line Garnero; Francis Eustache; Stéphane Lehéricy
Journal:  Radiology       Date:  2008-05-05       Impact factor: 11.105

View more
  9 in total

Review 1.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

2.  Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort.

Authors:  Shannon L Risacher; Li Shen; John D West; Sungeun Kim; Brenna C McDonald; Laurel A Beckett; Danielle J Harvey; Clifford R Jack; Michael W Weiner; Andrew J Saykin
Journal:  Neurobiol Aging       Date:  2010-08       Impact factor: 4.673

Review 3.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

4.  Joint analysis of structural and perfusion MRI for cognitive assessment and classification of Alzheimer's disease and normal aging.

Authors:  Duygu Tosun; Pouria Mojabi; Michael W Weiner; Norbert Schuff
Journal:  Neuroimage       Date:  2010-04-18       Impact factor: 6.556

5.  Classification of mild cognitive impairment and Alzheimer disease using model-based MR and magnetization transfer imaging.

Authors:  R Wiest; Y Burren; M Hauf; G Schroth; J Pruessner; M Zbinden; K Cattapan-Ludewig; C Kiefer
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-11       Impact factor: 3.825

Review 6.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Li Shen; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-07       Impact factor: 21.566

7.  DTI and MR Volumetry of Hippocampus-PC/PCC Circuit: In Search of Early Micro- and Macrostructural Signs of Alzheimers's Disease.

Authors:  F Palesi; P Vitali; P Chiarati; G Castellazzi; E Caverzasi; A Pichiecchio; E Colli-Tibaldi; F D'Amore; I D'Errico; E Sinforiani; S Bastianello
Journal:  Neurol Res Int       Date:  2011-06-12

8.  Windows on the human body--in vivo high-field magnetic resonance research and applications in medicine and psychology.

Authors:  Ewald Moser; Martin Meyerspeer; Florian Ph S Fischmeister; Günther Grabner; Herbert Bauer; Siegfried Trattnig
Journal:  Sensors (Basel)       Date:  2010-06-08       Impact factor: 3.576

9.  Elevated plasma levels of exosomal BACE1‑AS combined with the volume and thickness of the right entorhinal cortex may serve as a biomarker for the detection of Alzheimer's disease.

Authors:  Dewei Wang; Ping Wang; Xianli Bian; Shunliang Xu; Qingbo Zhou; Yuan Zhang; Mao Ding; Min Han; Ling Huang; Jianzhong Bi; Yuxiu Jia; Zhaohong Xie
Journal:  Mol Med Rep       Date:  2020-05-05       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.